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Abstract
Purpose: Patients with severe community-acquired pneumonia (CAP) are believed to have an ex-
aggerated inflammatory response to bacterial infection. Therapies aiming to modulate the inflam-
matory response have been largely unsuccessful, perhaps reflecting that CAP is a heterogeneous
disorder that cannot be modulated by a single anti-inflammatory approach. We hypothesize that
the host inflammatory response to pneumonia may be characterized by distinct cytokine patterns,
which can be harnessed for personalized therapies.
Methods: Here, we use hierarchical cluster analysis of cytokines to examine if patterns of inflam-
matory response in 13 hospitalized patients with CAP can be defined. This was a secondary data
analysis of the Community-Acquired Pneumonia Inflammatory Study Group (CAPISG) database.
The following cytokines were measured in plasma and sputum on the day of admission: inter-
leukin (IL)-1β , IL-1 receptor antagonist (IL-1ra), IL-6, CXCL8 (IL-8), IL-10, IL-12p40, IL-17, in-
terferon (IFN)γ, tumor necrosis factor (TNF)α, and CXCL10 (IP-10). Hierarchical agglomerative
clustering algorithms were used to evaluate clusters of patients within plasma and sputum cy-
tokine determinations.
Results: A total of thirteen patients were included in this pilot study. Cluster analysis identi-
fied distinct inflammatory response patterns of cytokines in the plasma, sputum, and the ratio of
plasma to sputum.
Conclusions: Inflammatory response patterns in plasma and sputum can be identified in hos-
pitalized patients with CAP. Characterization of the local and systemic inflammatory response
may help to better discriminate patients for enrollment into clinical trials of immunomodulatory
therapies.
DOI: 10.18297/jri/vol1/iss1/1/
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1 Introduction
Even with appropriate antibiotic therapy, some hospitalized pa-
tients with community-acquired pneumonia (CAP) progress to
clinical failure and death. High cytokine levels produce an exag-
gerated inflammatory response, known as the cytokine storm, and
may drive poor clinical outcomes. As a result, investigators have
evaluated the use of immunomodulatory agents in an attempt
to control this exaggerated inflammatory response and reduce
patient mortality. Corticosteroids are the primary immunomod-
ulatory agents considered for patients with CAP, and results of
several investigations1–10 have been evaluated in recent system-
‡Correspondence To: Timothy Wiemken
MedCenter One 501 E. Broadway 120B Louisville, Kentucky 40202, USA
Phone: 502-852-4627 Email: tim.wiemken@louisville.edu
atic reviews and meta-analyses11,12 Although steroids are con-
sidered important immunomodulatory agents for these patients,
other considerations include macrolides13–18 statins19–29 and tis-
sue factor pathway inhibitor30.
Severe pneumonia at the time of hospital admission is the primary
criterion for patient enrollment into clinical trials of immunomod-
ulatory therapies10,31. This is due to a general consensus that
severity of disease and the inflammatory response are positively
correlated. If this is the case, patients with more severe pneumo-
nia should present with an exaggerated inflammatory response
and would be ideal candidates for enrollment into trials of im-
munomodulatory therapies. Although this inflammation-severity
correlation may be true at the population level, increased disease
severity at the individual level may also be impacted by factors
© ULJRI 2017 Vol 1, (1) 3–11 | 3
unrelated to the inflammatory response. For example, a patient
hospitalized with CAP with a prior history of congestive heart fail-
ure who develops severe respiratory deterioration due to cardio-
genic pulmonary edema may not have an exaggerated inflamma-
tory response. Any patient without an exaggerated inflammatory
response, regardless of disease severity, would not be an appropri-
ate candidate for a trial of an immunomodulatory therapy. Sev-
eral experts in the field have indicated that the failure of many
recent investigations into immunomodulation in hospitalized pa-
tients with CAP is likely to be related to our inability to properly
characterize the patients who would benefit from these therapies
prior to enrollment32,33. To address this concern, methods to
better identify patients with and without an exaggerated inflam-
matory response are needed. We hypothesize that patients with
CAP can be clustered into distinct inflammatory response groups
at the time of hospital admission using cytokine levels in plasma
and/or sputum.
The objective of this study was to evaluate the utility of hierar-
chical agglomerative cluster analysis of plasma and sputum cy-
tokines to examine if inflammatory patterns can be defined in
hospitalized patients with CAP.
2 Methods
2.1 Study design and setting
This was a secondary data analysis of data previously col-
lected from the Community-Acquired Pneumonia Inflammatory
Study Group (CAPISG). An in-depth description of the CAPISG
study and specimen collection has been previously published34.
Briefly, we prospectively enrolled non-consecutive adult patients
hospitalized with CAP at the University of Louisville Hospital,
Louisville, Kentucky, USA, from 01 April 2011 to 01 August 2012.
The study protocol required enrolled patients to provide blood
and sputum specimens on the day of admission and at regular
intervals during hospitalization.
2.2 Study population
Adult patients with CAP in whom both blood and sputum spec-
imens were obtained on the day of admission were included in
the current pilot study. CAP was defined as a new pulmonary
infiltrate (within 24 hours of admission), associated with at least
one of the following criteria: a new or increased cough, an abnor-
mal temperature (<35.8 ◦C or >37.8 ◦C), or an abnormal leuko-
cyte count (leukocytosis, leukopenia or the presence of immature
neutrophils). Pneumonia was defined as community-acquired if a
patient had no history of hospitalization during the 2 weeks prior
to admission. Patients were excluded if they had a medical history
that, in the investigator’s opinion, precluded subject compliance
with the protocol.
2.3 Data sources and measurements
After patient consent, trained study coordinators and/or research
associates collected clinical data from the patient’s medical record
onto a paper case report form. A separate research associate en-
tered these data into a secure, web-based data management sys-
tem hosted by the University of Louisville Division of Infectious
Diseases. Data quality issues identified by the research associate
entering the data were fixed prior to submission of the case to
the database. The database also contains several data quality
checks to limit out-of-range errors and inappropriate data types.
These data quality structures were built in based on our decades
of experience collecting and entering clinical data into electronic
databases. After all data queries were resolved, the case was ac-
cepted into the database for analysis. The following clinical vari-
ables were collected and evaluated:
1. Demographics: age and sex
2. Comorbid conditions: chronic obstructive pulmonary dis-
ease (COPD), cerebrovascular disease, congestive heart fail-
ure, chronic renal disease, diabetes mellitus, active coro-
nary artery disease, neoplastic disease, neurologic dis-
ease/mental illness, acute renal disease, hyperlipidemia,
HIV status, ACE inhibitor use, aspirin use, beta blocker use,
heparin use, statin use, hospitalization for 2 or more days
in the prior 90 days, home infusion therapy, home oxygen
therapy, nursing home resident, and atrial fibrillation.
3. Physical examination: oral temperature, heart rate, respi-
ratory rate, systolic blood pressure, and diastolic blood pres-
sure.
4. Laboratory tests: pH, FiO2, PaCO2, serum bicarbonate,
serum blood urea nitrogen (BUN), serum creatinine, serum
glucose, hematocrit, hemoglobin, serum potassium, serum
sodium, platelet count, procalcitonin, and white blood cell
count (WBC).
5. Severity of CAP: need for ICU admission on arrival, altered
mental status, vasopressors, IV steroids on admission, and
the Pneumonia Severity Index.
All microbiological evaluations were done according to clinical
needs per hospital microbiology protocols.
2.4 Specimen collection and processing
2.4.1 Plasma
Blood samples were obtained on the day of admission to the
hospital. Venous blood was collected using sodium citrate BD
Vacutainer R©tubes and processed within 2 hours of collection.
The tubes were centrifuged at 300× g for 10 minutes and the
plasma separated by aspiration, aliquoted (0.5 ml each) and
stored frozen at -80 ◦C until assayed.
2.4.2 Sputum
Sputum samples were obtained on the day of admission to the
hospital and processed within 2 hours of collection, according
to the method described by Pizzichini et al.35. Briefly, samples
were diluted with an equal amount of a 0.1% Dithiothreitol solu-
tion in phosphate buffered saline (PB and incubated in a rocking
platform for 15 minutes in order to digest the mucus. An equal
volume of sterile saline was added, followed by an additional 5
minutes of incubation. The samples were then filtered through
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Table 1 Patient Characteristics
Variable Patient Identification Number
1 2 3 4 5 6 7 8 9 10 11 12 13
Sex Male Female Male Female Male Male Female Female Female Male Male Male Male
Age (years) 78 54 40 51 63 62 72 57 53 78 85 65 59
Obese (BMI>30 kg/M2) No Yes No Yes No No Yes Yes No No No No No
Immunocompromized No No Yes Yes No Yes Yes No Yes Yes No Yes Yes
ICU admission Yes No No No No No No No Yes No Yes No Yes
Nursing home resident No No No No No No No Yes No No No No Yes
Active cancer No No No No No Yes Yes No No Yes No No No
Liver disease No No No No No No No No No No No No No
Renal disease No No No No Yes No No No No No No No No
Congestive heart failure No No No Yes No No Yes Yes No Yes No No No
Cerebrovascular disease No No No No No No No Yes No No Yes No No
Altered mental status No No No No No No No No No Yes No No No
Heart rate, (beats/min) 91 130 98 78 93 87 118 108 77 94 156 92 102
Respiratory rate breaths/min 18 22 24 16 22 20 28 24 28 20 40 25 25
Systolic blood pressure (mmHg) 95 144 114 135 99 115 187 166 185 133 99 151 90
Oral temperature (F) 99 100 100 98.7 100.4 98.6 102 101 101 99.2 100 97.5 98
Hematocrit (%) 41.4 48.8 38 40.3 42.5 35 34 43.5 36.1 31.8 43.2 34.2 37.7
Blood urea nitrogen mg/dl 13 16 13 22 36 40 10 31 5 70 21 10 13
Sodium mmol/litre 137 134 140 133 133 129 140 133 140 146 140 139 138
Arterial pH No ABG 7.36 No ABG 7.46 No ABG 7.41 No ABG 7.39 7.44 No ABG 7.41 7.414 No ABG
PaO2 mmHg No ABG 59 No ABG 60 No ABG 67 No ABG 94 66 No ABG 78.4 65.9 No ABG
Glucose mg/dl 116 97 101 295 88 102 105 185 107 108 179 111 174
Pleural effusion No Yes No No No No No Yes No No Yes No Yes
Pneumonia Severity Index risk class Class III Class III Class I Class II Class IV Class V Class IV Class IV Class II Class V Class V Class II Class III
Days to clinical stability 2 2 7 2 3 Unknown 4 6 4 2 6 2 3
Culture positive Yes Yes Yes Yes No Yes No No No No No Yes No
Length of stay (days) 3 4 8 3 3 15 6 6 6 6 6 2 9
In-hospital mortality No No No No No Yes No No No No No No Yes
nylon gauze and centrifuged at 790×g for 10 minutes. The cell-
free supernatants were aliquoted and stored frozen at -80 ◦C until
used for the measurement of cytokine levels.
2.5 Cytokine measurements
Laboratory methods for cytokine measurements have been pre-
viously published34. The concentrations of interleukin (IL)-1β ,
IL-1 receptor antagonist (IL-1ra), IL-6, CXCL8 (IL-8), IL-10, IL-
12p40, IL-17, interferon (IFN)γ, tumor necrosis factor (TNF)α,
and CXCL10 (IP-10) in plasma and sputum samples were deter-
mined using Milliplex MAP Multiplex kits (EMD Millipore, Biller-
ica, MA). Following thawing, plasma and processed sputum sam-
ples were centrifuged at 10,000×g for 5 min and the supernatants
used in the assay according to the manufacturer’s instructions
2.6 Compliance with Ethical Standards
The University of Louisville Human Subjects Program Protection
Office approved this study prior to any data collection (approval
number: 07.0182). Informed consent was obtained from all indi-
vidual participants included in the study.
2.7 Statistical analysis
For each patient, cytokine values were scaled by subtracting the
mean cytokine value across all patients from each particular pa-
tient cytokine level. This value was then divided by the stan-
dard deviation of the particular cytokine. The scale function in
Rv3.2.0 (R Foundation for Statistical Computing, Vienna, Aus-
tria) was used for scaling purposes. Hierarchical agglomerative
clustering algorithms were then used to evaluate clusters of pa-
tients within the plasma and sputum determinations separately.
Finally, the plasma determination was divided by the sputum de-
termination and the same clustering methods were used to eval-
uate clusters from the plasma/sputum ratio. Ensemble cluster-
ing methods were used to identify the most appropriate distance
metric and cluster linkage function for hierarchical agglomerative
cluster analysis36. From these results, the distance metric and
linkage function providing the most clinically meaningful clus-
tering were chosen. For each clustering algorithm, dendrograms
and heatmaps were created to visualize the clusters and scaled
cytokine values. Dark blue colors on the heatmaps represent high
cytokine values, white colors represent average values, and dark
red represent low values. To compare plasma and sputum clus-
tering dendrograms, we used the Pearson cophenetic correlation
statistic. Briefly, cophenetic correlation statistics are similar to
traditional correlation measures, ranging from -1 (perfect nega-
tive correlation) to +1 (perfect positive correlation), with a zero
being no correlation.
To compare differences in patient characteristics between groups
defined as having a higher inflammatory response versus a lower
inflammatory response from the cluster analysis, frequencies and
percentages for categorical variables and medians with interquar-
tile ranges were presented for continuous variables. Statistical
hypothesis testing was not done due to the probability of error
in the multiple tests and the limited number of patients included
in the study. R v3.2.0 (R Foundation for Statistical Computing,
Austria) was used for all analyses. The following R packages and
were used: gplots37, dendextend38, dendextendRcpp39, clue36,
and RColorBrewer40.
3 Results
3.1 Demographic, clinical and laboratory findings
A total of 13 patients were included in this pilot study. Baseline
patient characteristics and clinical outcomes for each of the 13
patients can be found in Table 1. No patients were started on va-
sopressors on admission or during hospitalization. For higher vs
lower inflammatory phenotype groups identified via cluster anal-
© ULJRI 2017 Vol 1, (1) 3–11 | 5
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Fig. 1 Heatmaps and dendrograms for cytokines in sputum and plasma. Each heatmap and dendrogram depict some separation of patients’
inflammatory response. The cophenetic correlation coefficient comparing the clustering of patients in plasma and sputum determinations was 0.14,
suggesting low correlation between plasma and sputum clusterings. a horizontal line was drawn to indicate a suggested separation of inflammatory
response patterns based on the cluster dendrograms and visual inspection of the heatmaps.
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ysis of the sputum specimens patients with a higher inflammatory
phenotype had a lower rate of ICU admission (0% vs 67%, re-
spectively). Similarly, when evaluating plasma cytokine profiles,
patients with a higher inflammatory phenotype had a lower rate
of ICU admission versus those with a lower inflammatory pheno-
type (12% vs 60%, respectively). This difference did not remain
when evaluating the plasma/sputum ratio. No other clinically
meaningful differences were identified.
A pathogen was identified in 6 of the 13 patients. Streptococcus
pneumoniae was identified in patients 1, 4, and 12, influenza in
patient 2, Pseudomonas aeruginosa in patient 3, and methicillin-
resistant Staphylococcus aureus in patient 6.
3.2 Cytokine profiles
Based on the results of ensemble clustering, Euclidean distance
and Ward’s D linkage metrics were identified as the most clinically
meaningful for our needs. Each heatmap and dendrogram depict
some separation of patients’ inflammatory response. A heatmap
and dendrogram for cytokines in sputum is depicted in Figure 1a.
A heatmap and dendrogram for cytokines in plasma is depicted
in Figure 1b. The cophenetic correlation coefficient comparing
the clustering of patients in plasma and sputum determinations
was 0.14, suggesting low correlation between plasma and spu-
tum clusterings. A heatmap and dendrogram for cytokines in
plasma/sputum ratio is depicted in Figure 1c. In each figure,
a horizontal line was drawn to indicate a suggested separation
of inflammatory response patterns based on the cluster dendro-
grams and visual inspection of the heatmaps.
4 Discussion
This pilot study suggests that it may be possible to identify distinct
cytokine patterns in plasma and sputum in hospitalized patients
with CAP at the time of hospital admission. We found that approx-
imately half of the patients were in each inflammatory response
group across analysis of sputum cytokines, plasma cytokines, and
the plasma/sputum cytokine ratio. Several patients were retained
in the same group in all 3 analyses. Since this was a pilot study,
larger studies may identify more than the two patterns identi-
fied in our study. The only clinically relevant difference identi-
fied in the patient characteristics comparisons between high vs
low inflammatory phenotypes was the need for direct ICU ad-
mission when comparing both sputum and plasma cytokines. In
both comparisons, patients with lower inflammatory phenotypes
necessitated more intensive care on admission compared to those
with higher inflammatory phenotypes. With our small sample size
it is unclear as to if these differences are real or due to chance
however this may be an interesting variable to evaluate in future
larger studies. For sputum cytokines, it is possible that patients
with a lower inflammatory response on admission have a poor
local immune response and may end with a more severe disease
leading to ICU admission.
A timeline of the inflammatory response in patients with pneumo-
nia can be generalized as follows (Figure 2): At time zero, during
the initial invasion of organisms into the alveolar space, there is
an interaction of the invading pathogen with cells of the innate
immune system. The identification of the pathogen is made by
receptors called pattern recognition receptors (PRR). Streptococ-
cus pneumoniae, as well as other extracellular pathogens may
be recognized by a family of membrane-bound PRPs called Toll-
like receptors. Influenza and other intracellular pathogens may
be recognized by a family of cytoplasmic PRPs called NOD-like
receptors.
During the initial 24 hours after infection, activation of theses re-
ceptors will trigger synthesis and secretion of cytokines. Since dif-
ferent pathogens are recognized by different receptors with differ-
ent signaling mechanisms, it is predictable that the initial inflam-
matory response may be pathogen specific. On the other hand,
the inflammatory response will also be host specific, as the initial
cytokine response will be different in patients with different un-
derlying medical conditions, who have chronic inflammation, or
who are taking medications that may modulate the inflammatory
response. Due to the multiple pathogen and host factors that may
influence the inflammatory response, the initial cellular response
and cytokine pattern is likely to be pathogen and host specific.
On days two and three post infection, a well-developed lung in-
flammatory response should be present. The initially specific in-
flammatory response may begin to evolve into non-specific in-
flammatory pathways. At this time, the local lung inflammatory
response may spill over into the circulatory system, generating a
systemic inflammatory response.
Patients with pneumonia are hospitalized with an average of 3
to 5 days of signs and symptoms. By this time, we hypothesized
that patients present with two patterns of inflammatory response,
one associated with repair, and another associated with injury, as
depicted in Figure 2. We further hypothesized that these patterns
of response can be identified by performing a cluster analysis of
cytokines at the time of hospital admission. In the current pilot
study, we were able to characterize patterns of local (sputum) and
systemic (plasma) inflammatory response in hospitalized patients
with pneumonia.
We speculate that patients with an exaggerated inflammatory pat-
tern only in the sputum may not be ideal candidates for clinical
trials of immunomodulatory therapies, since a local immune re-
sponse is an appropriate physiologic response to pneumonia. Re-
ducing a non-exaggerated immune response may not be thera-
peutic, could bias a trial’s results to the null, and could even lead
to poor outcomes. However, patients with an exaggerated inflam-
matory response in the circulation may be excellent candidates
for these trials due to their systemic cytokine storm. As depicted
in Figure 2, 8 of the 13 CAP patients in our study appeared to
have an exaggerated inflammatory response in plasma. These pa-
tients would be appropriate candidates for immunomodulation.
Since this was a pilot study, we enrolled a limited number of pa-
tients. Evaluating only these 13 patients limits the generalizabil-
ity. Furthermore, this small sample size allows for potentially bi-
ased cluster analyses. Another limitation of our study is that the
line separating our definition of the exaggerated inflammatory re-
© ULJRI 2017 Vol 1, (1) 3–11 | 7
Fig. 2 A timeline of the inflammatory response in patients with pneumonia
sponse was partially based on visual inspection of the heatmap.
This may lead to misclassification of some patients due to the
partially subjective nature of this classification. Not all aspects of
inflammation and anti-inflammation were evaluated in this study.
Other makers may be important for determining an exaggerated
inflammatory response to infection. Another limitation is that
the bacterial burden was not measured. This can influence in-
flammatory response and bias the clustering results. One possible
strength of our study is the ability of the cluster analysis to nor-
malize cytokine values without dependence on a single cytokine
value that may be pro- or anti-inflammatory on its own.
These interesting results suggest a prospective study with a larger
number of patients is warranted, with the goal to characterize
patterns of inflammatory response in blood and sputum in pa-
tients with CAP at the time of hospital admission. In this study,
it will be important to evaluate variables that may confound
the inflammatory response such as etiology of CAP, the use of
steroids, and the use of macrolide antibiotics. Furthermore, if cy-
tokine values were to be determined immediately upon admission
each value could be automatically uploaded to and analyzed by a
cloud-based application using supervised machine learning algo-
rithms. Results of the analysis could be reported back to a mobile
device in real-time as a yes/no decision rule. This would allow for
rapid determination of the level of inflammation to define candi-
dacy into clinical trials for immunomodulatory therapies.
In conclusion, we were able to define patterns of inflammatory
response using cytokine data in this pilot study. Our results sug-
gest that airway and systemic inflammation in CAP is heteroge-
neous, providing proof of principle that stratification based on
the inflammatory patterns may be possible for future trials of im-
munomodulation.
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